Please wait while we load the requested 20-F report or click the link below:
https://last10k.com/sec-filings/report/1553846/000114420413009918/v335542_20f.htm
May 2022
May 2022
May 2022
May 2022
May 2022
April 2022
April 2022
March 2022
March 2022
March 2022
Please wait while we load the requested 20-F report or click the link below:
https://last10k.com/sec-filings/report/1553846/000114420413009918/v335542_20f.htm
Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Redhill Biopharma Ltd..
Redhill Biopharma Ltd.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Redhill Biopharma Ltd. provided additional information to their SEC Filing as exhibits
Ticker: RDHL
CIK: 1553846
Form Type: 20-F Annual Report
Accession Number: 0001144204-13-009918
Submitted to the SEC: Tue Feb 19 2013 12:25:37 PM EST
Accepted by the SEC: Tue Feb 19 2013
Period: Monday, December 31, 2012
Industry: Pharmaceutical Preparations